Table 2.
Baseline characteristics and outcomes of the TKA group
| Author | Year | Country | Study_design | No. Knees | No. Patients | Age (mean ± SD) | BMI (mean ± SD) | Follow-up, months (mean ± SD) | Reoperation | Revision | Infection | Readmission | Complication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J.W.Staeheli | 1987 | USA | Case–control | 35 | 35 | 67.3 ± 9.7 | NR | 44 ± 11.5 | 9 | 1 | 1 | NR | NR |
| A.Amendola | 1989 | Canada | Case–control | 42 | 39 | 64 ± 7.5 | NR | NR | 4 | 2 | 1 | NR | 5 |
| T.Gill | 1995 | USA | Case–control | 30 | 27 | 65 ± 5.5 | NR | NR | 6 | 1 | NR | NR | 5 |
| Sören Toksvig-Larsen | 1998 | Sweden | Retrospective cohort | 40 | 40 | 69 ± 6.0 | NR | NR | 4 | 4 | NR | NR | NR |
| F.S.Haddad | 2000 | England | Case–control | 50 | 42 | NR | NR | NR | 15 | 2 | 1 | 2 | NR |
| J.B.Meding | 2000 | USA | Case–control | 95 | 82 | 66.2 ± 8.7 | NR | 103.2 ± 45 | 14 | 1 | 6 | NR | 11 |
| T.Noda | 2000 | Japan | Retrospective cohort | 28 | 23 | 69.4 | NR | 25 ± 27.5 | NR | NR | NR | NR | 7 |
| Bob Karabatsos | 2002 | Canada | Retrospective cohort | 20 | 20 | 64 ± 8.2 | NR | 62.4 | 1 | 0 | 1 | NR | 3 |
| P.Haslam | 2007 | England | Case–control study | 51 | 40 | 78 | NR | 151.2 ± 30.0 | 31 | 8 | 3 | NR | 34 |
| K.J.Kazakos · | 2008 | Greece | Retrospective cohort | 38 | 32 | 67.2 ± 7.0 | NR | Not reported | NR | NR | 1 | NR | 1 |
| Y.Akasaki | 2009 | Japan | Case series | 20 | 20 | 72 ± 7.0 | NR | 61.2 ± 14.7 | 0 | 0 | NR | NR | NR |
| D.K.Bae | 2010 | Korea | Retrospective cohort | 16 | 13 | 64.9 ± 6.2 | 27.22 | 56.4 ± 30.9 | NR | NR | NR | NR | NR |
| H.Orban | 2011 | Romania | Case series | 16 | 16 | 64.3 | 25.8 | 51.6 | NR | NR | NR | NR | NR |
| S.Treuter | 2012 | Germany | Case series | 48 | 48 | NR | NR | 159.6 ± 16.5 | 1 | NR | NR | NR | 3 |
| Luis A. Farfalli | 2012 | Argentina | Retrospective cohort | 34 | 31 | 67 ± 9.0 | NR | 96 ± 51.7 | 16 | 8 | 3 | NR | 12 |
| H.Gupta | 2013 | India | Retrospective cohort | 58 | 55 | 61.9 ± 7.5 | 29.6 ± 3.2 | 134.4 ± 45.0 | 11 | 4 | 4 | NR | 10 |
| P.Hernigou | 2013 | France | Case–control | 50 | 50 | 65 ± 6.7 | NR | 180 ± 30.0 | 2 | 2 | NR | NR | 2 |
| G.A.Valenzuela | 2013 | USA | Case–control | 18 | 15 | 64.2 ± 10.2 | 33 ± 4.5 | NR | 4 | 2 | NR | NR | 4 |
| T.Niinimaki | 2014 | Finland | Case–control | 1036 | 1036 | 64.3 ± 14.2 | NR | 80.4 ± 66.0 | 93 | 93 | 14 | NR | NR |
| A.Dahl | 2016 | Sweden | Case–control | 119 | 119 | 63 ± 7.7 | 29.1 ± 3.5 | NR | 5 | 5 | NR | NR | NR |
| D.K.Bae | 2017 | South Korea | Case–control | 32 | 29 | 68.3 ± 6.2 | 26.6 ± 2.4 | 74.4 ± 48.0 | 0 | 0 | NR | NR | 0 |
| J.B.T.Lim | 2017 | Singapore | Case–control | 217 | 217 | 64.5 ± 7.3 | 28.9 ± 5.0 | 24 | 15 | 3 | 8 | NR | 15 |
| M.Ehlinger | 2017 | France | Retrospective cohort | 135 | 135 | 63.2 | NR | 88.9 ± 32.5 | 16 | 11 | 2 | NR | 11 |
| X.P.Carnero | 2018 | Spain | Case–control | 41 | 41 | 70 ± 8.0 | 31.2 | 145.2 | NR | NR | 0 | NR | 0 |
| B.Chalmers | 2019 | USA | Case–control | 231 | 207 | 64 ± 12.2 | 31 ± 8.0 | 96 ± 45 | 52 | 20 | 5 | NR | 14 |
| Anders El-Galaly | 2019 | Denmark | Retrospective cohort | 1155 | 1155 | 63 ± 14.5 | NR | 111.6 ± 74.6 | 101 | 101 | NR | NR | 18 |
| C.Batailler | 2020 | France | Case–control | 41 | 41 | 65.4 ± 8.4 | 31.4 ± 4.1 | 93.6 ± 28.8 | 1 | 1 | 2 | NR | 9 |
| A.Parente | 2021 | Italy | Case–control | 33 | 33 | 74 ± 11.2 | 25 ± 2.1 | 134.4 ± 36 | 4 | 2 | NR | NR | 0 |
| C.A.Primeau | 2021 | England | Retrospective cohort | 103 | 103 | 50.2 ± 6.7 | 31 ± 5.6 | NR | NR | NR | NR | NR | NR |
| SunHo Lee | 2021 | South Korea | Retrospective cohort | 2177 | 2177 | 62.9 ± 6.5 | NR | 120 | 44 | 44 | 74 | NR | 592 |
| J.Song | 2022 | Singapore | Retrospective cohort | 159 | 159 | 66.0 ± 8.0 | 28.1 ± 5.3 | 24 | NR | NR | 3 | NR | 2 |
| J.Erard | 2023 | France | Case–control | 73 | 73 | 64.9 ± 9.1 | 29.1 ± 5.5 | 159.6 ± 39.6 | 14 | 6 | 1 | NR | 8 |
| Ahmed M. Abdelaal | 2023 | Egypt | Case series | 33 | 31 | 64.6 ± 4.5 | 28 ± 4.1 | 51.6 ± 13.2 | 4 | 0 | 2 | NR | 7 |
| Francesco Pardo | 2024 | Italy | Retrospective cohort | 383 | 383 | NR | NR | 116.4 ± 60.0 | 28 | 28 | NR | NR | NR |
| Tianshun Xie | 2024 | Netherlands | Retrospective cohort | 65 | 65 | 62.6 ± 6.0 | 31.4 ± 5.3 | 12 | NR | NR | NR | NR | 0 |
Abbreviations: SD standard deviation, OA osteoarthritis, ACL anterior cruciate ligament, BMI body mass index, MRI magnetic resonance imaging, HKA hip-knee-ankle angle, MPTA medial proximal tibial angle, NR not reported